Gvoke for subcutaneous injection is only available as a brand-name drug. It doesn’t come in a generic version. However, glucagon (the active drug in Gvoke) is available in generic forms for ...

Gvoke VialDx is expected to be available in the third quarter of 2025. The Food and Drug Administration (FDA) has approved Gvoke VialDx ™ (glucagon) for intravenous use as a diagnostic aid ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal radiologic exams, expanding the product's sales base beyond diabetic ...

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said Kevin McCulloch, President and COO of Xeris. "American Regent is the ...

In the US, Baqsimi is now competing head-to-head with Xeris’ Gvoke, pre-filled syringe and pen injector formulations of glucagon that don’t require the mixing steps and can be used in patients ...

Xeris has 3-4 approved products; these are: Gvoke (glucagon injection): Gvoke is the first autoinjector for severe hypoglycemia approved by the FDA. Keveyis (dichlorphenamide): The first FDA ...

The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the ...

The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic ...

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said Kevin McCulloch, President and COO of Xeris. "American Regent is the perfect ...